Current Advances in the Perioperative Treatment of Muscle-Invasive Bladder Cancer
Muscle-invasive bladder cancer (MIBC) is a highly aggressive disease with a significant risk of recurrence with metastatic disease. Neoadjuvant chemotherapy has been the preferred approach for cisplatin-eligible patients, with regimens such as dose-dense methotrexate, vinblastine, doxorubicin and ci...
Saved in:
| Main Authors: | Ursula Vogl, Giuseppe Salfi, Giovanna Pecoraro, Martino Pedrani, Ricardo Pereira Mestre, Marialuisa Puglisi, Fabio Turco |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2025-06-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2025.24.184 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States
by: Caicong You, et al.
Published: (2025-07-01) -
Current capabilities of endoscopic diagnosis of non-muscle invasive bladder cancer
by: I. N. Zaborskii, et al.
Published: (2020-06-01) -
Predictors of Outcome of Non–Muscle-Invasive and Muscle-Invasive Bladder Cancer
by: Ramy F. Youssef, et al.
Published: (2011-01-01) -
Advances in bladder preservation therapy for muscle-invasive bladder cancer
by: Ran Zhang, et al.
Published: (2025-05-01) -
Neoadjuvant immunotherapy driven bladder preservation for muscle invasive bladder cancer
by: Jiao Hu, et al.
Published: (2025-08-01)